To include your compound in the COVID-19 Resource Center, submit it here.

Vertex advancing CFTR corrector VX-659 to Phase III

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported data from 63 cystic fibrosis patients with one copy of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation and one minimal function mutation in Part 1 of

Read the full 348 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE